As self-funding continues to draw the attention of employers and benefits advisors, a number of questions, challenges and opportunities have arisen, leaving many employers and advisors uncertain about how and when to consider making a change. 

BenefitsPRO recently caught up with Josh McGee, Vice President of Program Development at Stealth Partner Group, an Amwins Group Company, to discuss the latest trends and strategies when it comes to self-funded plans and specific coverages like gene therapy. 

BenefitsPRO: Have there been any trends you've noticed in how self-insured employers have navigated the growing complexities of healthcare coverage like gene therapy?

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events
  • Access to other award-winning ALM websites including and

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.